Monday, September 25, 2017
 
 
Company News: Page (1) of 1 - 03/19/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
AstraZenecas CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Hospitalizations for Heart Failure and Death versus Other Type-2 Diabetes Medicines

(March 19, 2017)
Our Apologies, This article is no longer available, You may have followed an outdated link.


Page: 1


Related Keywords:
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
Seniors

Drugs
  • The High-Tech Future of Home Healthcare
  • Global Spectroscopy Market (2017-2022): Analysis By Technology, Applications & Geography - Research and Markets
  • A Medical Implants Manufacturer Used Salesforce Effectiveness Solution to Improve Salesforce Performance Provided by Quantzig
  • Point of Care Technology Market :Company information, geographical data and Market Analysis
  • Dental Market Trends, Size, Growth, Leading Players, Opportunities and 2021 Global Analysis Forecasts Discussed in New Research Report

    Cancer
  • Targovax granted US Patent for mutant-RAS neoantigen platform lead products
  • Sonnet Biotherapeutics to present data on bispecific platform candidates at AACR and SITC Annual Meetings
  • RAD Technology Medical Systems Launches their Newest Product - Healing Portals
  • Cannabics Pharmaceuticals Files National Phase Applications for Its System and Method for High Throughput Screening of Cancer Cells
  • FACIT Congratulates Portfolio Company Fusion Pharmaceuticals on its US$46 Million Oversubscribed Series A
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines